AI in Regulatory Intelligence

FDA Grants Full Approval to Tecartus for Relapsed Mantle Cell Lymphoma. Here Is What That Means for Biotech Operators. On April 3, 2026, the FDA converted Tecartus from accelerated to full approval for adult patients with relapsed or refractory mantle cell lymphoma (MCL). For CAR-T commercial teams, market access functions, and specialty operations leaders, this […]

FDA Grants Full Approval to Tecartus for Relapsed Mantle Cell Lymphoma. Here Is What That Means for Biotech Operators. On April 3, 2026, the FDA converted Tecartus from accelerated to full approval for adult patients with relapsed or refractory mantle cell lymphoma (MCL). For CAR-T commercial teams, market access functions, and specialty operations leaders, this

AI post-approval regulatory monitoring: how to stay ahead of lifecycle obligations Approval is not the finish line. It is where the regulatory workload begins. Labelling variations. REMS updates. Post-marketing commitments. PSURs. Regulatory intelligence monitoring across every authorised market. For a biotech with products in 30 or 40 countries, managing the post-approval regulatory landscape is a